Research Spotlight: Dr Stephen Mattarollo

Research Spotlight: Dr Stephen Mattarollo

This month, we welcome Cure Cancer Australia alumnus Dr Stephen Mattarollo to our Research Consultative Committee

Stephen+Motorollo+615x410.png

Stephen joined the research group led by Professor Ian Frazer at The University of Queensland Diamantina Institute in 2007 to undertake postdoctoral research, investigating immune regulation in animal models of cervical cancer.

In 2010, he furthered his training in the field of cancer immunotherapy by secondment to the laboratory of Professor Mark Smyth at the Peter MacCallum Cancer Centre in Melbourne. There, he and his group developed a novel therapeutic cancer vaccine for B cell lymphomas, and through collaboration with international colleagues in France, made significant inroads into understanding how the immune system is required for effective chemotherapy treatment outcomes in cancer patients.

Returning to UQDI in May 2012, Stephen established his own group whose vision and goal is to develop and promote blood cancer immunotherapies at the Translational Research Institute and UQ.

Immune Based Therapies

Stephen’s group focuses on developing and assessing combination immune-based therapies in mouse models of cancer, and investigating how tumours escape control by the immune system. They are also interested in how external ‘modifiable’ factors - such as chronic stress - impact on the immune system and on immunotherapy.

“Our vision is to try and incorporate immune-based therapies with conventional therapies for cancer,” says Stephen. “Current therapies are very toxic and don’t always work that well, particularly in patients who have resistant tumours or have relapsed to disease. By combining immune-based therapies with conventional treatments, we hope to boost the overall effect and create more durable responses to different types of cancer.”

Stephen and Cure Cancer Australia

Stephen was funded by Cure Cancer Australia in 2015/16 for a project which aimed to develop a therapeutic antibody vaccine for B cell lymphomas. We are delighted that Stephen has joined the Cure Cancer Australia Research Consultative Committee and look forward to working with him over the coming years, starting with our Research Symposium in May.

About the Research Committees

Research activity at Cure Cancer Australia is guided by the Research Committee, headed by Professor Clare Scott; a member of the board of directors who is both a practicing clinician and a researcher.

The Research Committee exists to assist in the identification of suitable researchers for Cure Cancer Australia funded grants. They are also on hand to provide scientific advice to Cure Cancer Australia and its Board as required.

The Research Consultative Committee is made up of four mid-career researchers who have previously been funded by Cure Cancer Australia. The Committee provides advice to the Research Committee and the Research Program Manager from the mid-career researchers perspective and are a key organiser of our annual Researcher Symposium.

More information on the Research Committees can be found here.

 

One more thing...

With your help, we can continue to fund early-career researchers, like Dr Stephen Mattarollo, who are working across ALL cancers and ALL areas of cancer research.

... ...
Loading...